Nefecon

Calliditas Therapeutics is a commercial-stage biopharmaceutical company based in Stockholm, Sweden, specializing in the development of novel treatments for orphan diseases with high unmet medical needs, particularly in renal and hepatic conditions. The company's flagship product, Tarpeyo (Nefecon), is a targeted-release oral formulation of budesonide and the first FDA-approved therapy to reduce the loss of kidney function in adults with primary IgA nephropathy. Calliditas utilizes its proprietary Turecal technology to deliver active substances to specific regions of the gastrointestinal tract, maximizing local efficacy while reducing systemic side effects. In September 2024, Calliditas was acquired by Asahi Kasei Corporation, becoming a key part of its global pharmaceutical business. The company continues to advance its pipeline, including setanaxib, a NOX1/4 inhibitor being evaluated for multiple indications such as primary biliary cholangitis and Alport syndrome.